Loading
Life sciences · Review
Immunotherapy · November 6, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Review.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Nanobody-based chimeric antigen receptors (CARs) represent a promising strategy for improving the specificity, modularity, and clinical adaptability of cellular immunotherapies. Replacing conventional single-chain variable fragments with camelid-derived variable heavy-chain domains (VHHs) may enhance receptor stability, antigen accessibility, and construct design. This review summarizes nanobody-based CAR applications across T cells, natural killer (NK) cells, γδ T cells, and macrophages, drawing on literature published between 2011 and 2026 and identified through PubMed/MEDLINE, Scopus, Web of Science, and Google Scholar. Nanobody-based CAR-T cells support recognition of hematologic and solid tumors and facilitate dual targeting, tandem receptors, affinity tuning, and immune-modulating designs. CAR-NK cells combine antigen-directed activity with innate cytotoxicity and potential advantages for allogeneic, off-the-shelf treatment. CAR-γδ T cells integrate innate-like surveillance with engineered specificity and may offer reduced graft-versus-host disease risk. CAR-macrophages exploit phagocytosis and tumor microenvironment remodeling to promote antitumor responses. Emerging universal, switchable, -generated, and synthetic antigen-based CAR platforms further highlight the versatility of nanobodies for controllable and scalable therapies. Collectively, these approaches offer opportunities to address tumor heterogeneity, antigen escape, and treatment safety, although further preclinical optimization and rigorous clinical evaluation are needed to establish their efficacy, persistence, and long-term safety in diverse patient populations and clinical settings.